Sodium polyphosphate, a new drug for treatment of atopic dermatitis: basic considerations and clinical case studies Meik Neufurth, Hadrian Nassabi, Sanja Perovic-Ottstadt, Rita Dobmeyer, Rafael Muñoz-Espí, Hiroshi Ushijima, Heinz C Schröder, Changxin Wu, Xiaohong Wang, Werner E G Müller Abstract Atopic dermatitis is a serious, chronic inflammatory skin disease that can currently only be treated symptomatically. The rise in extracellular Ca2+ ions by mast cells and platelets, which acts as a death signal for neuronal cells, plays a crucial role in the pathogenesis of the disease. Both cell types produce the neurotransmitters histamine and serotonin and express the N-methyl-d-aspartate (NMDA) receptor on their surface. Here, we show that the physiological inorganic polymer polyphosphate (Na-polyP; when administered as the sodium salt), which is stored and released by platelets, can suppress the adverse effects in atopic dermatitis due to its unique ability to bind Ca2+ by coacervate formation. This eliminates the Ca2+ burst occurring in neural tissue damage by exchanging Na+ for Ca2+ ions. It is shown that the energy-rich Na-polyP, with a physiological chain length of approximately 50 phosphate residues, enhances the serotonin-induced neurite outgrowth in neuronal PC12 cells, even in the absence of the neurotransmitter and additional Ca2+ ions. In rat primary neuronal cells, Na-polyP completely prevented the histamine-caused apoptotic cell death. Based on the results of experiments with the indicator Fura 2-AM, which demonstrated an abolition of the histamine- and glutamate-induced rise in intracellular Ca2+ levels in neurons after addition of Na-polyP, we conclude that the neuroprotective effect of Na-polyP is due to the formation of polyP coacervate through Na+/Ca2+ exchange. Furthermore, it was found that Na-polyP enhances collagen fibrillogenesis, which is impaired in atopic dermatitis, as demonstrated by immunostaining and RT-qPCR experiments using human endothelial cells (HUVEC). The role of disease-relevant metalloproteinases induced by polyP was demonstrated in experiments with the inhibitor quercetin, using CD80 as a marker for pro-inflammatory M1 macrophages. Finally, studies in patients showed that Na-polyP embedded in a hydrogel can alleviate and heal atopic dermatitis lesions, indicating the potential of Na-polyP as a clinically applicable drug for treating the disease. A GMP-compliant Na-polyphosphate prevents atopic dermatitis by removing Ca2+ at the NMDA receptor. This finding is supported by both cell-based studies and successful outcomes in patients with atopic dermatitis.[d6bm00783j-ga.webp] Introduction In a previous study, we reported that the sodium salt of the physiological inorganic polymer polyphosphate (Na-polyP) exerts a strong neuroprotective effect on neurons isolated from 19-day-old Wistar rat embryos in vitro. This effect was explained at the molecular level by the Ca2+ binding and chelating properties of Na-polyP. During this process, polyP undergoes coacervation, a liquid–liquid phase separation that leads to a dense, gel-like phase, which is in thermodynamic equilibrium with a dilute aqueous phase. To investigate whether Na-polyP also has an ameliorating, neuroprotective effect in humans, we examined the effect of a hydrogel containing Na-polyP as the active component on the clinical picture of atopic dermatitis (also termed neurodermatitis). This is a very serious syndrome that places a heavy burden on patients and reduces their quality of life. Importantly, a meta-analysis focusing on the pattern of major neuropsychiatric diseases found a correlation between Alzheimer dementia and atopic dermatitis. The treatment of patients with atopic dermatitis is associated with high costs for the society; in Germany, for example, the mean annual cost per patient with mild atopic dermatitis is €1466 (standard deviation, SD = €3029), with a median cost of €551; with an estimated prevalence of 1.5 to 2 million in children and an additional 1 to 2 million in adolescents. Current therapies for atopic dermatitis have various limitations. The long-term or repeated use of topical and/or systemic corticosteroids, currently employed to treat or alleviate the symptoms of atopic dermatitis, can be associated with serious side effects, such as skin atrophy, metabolic complications (e.g., diabetes), impaired adrenal function, osteoporosis (bone loss), cataracts (clouding of the eye lens), high blood pressure, and an increased risk of infections. Treatment with Janus kinase (JAK) inhibitors or biologics can be associated with an increased risk of bacterial and viral infections. Moreover, they are costly. Furthermore, individual patients often respond differently to these various forms of treatment, underscoring the need for personalized therapy. Therefore, there is a need for additional strategies for the treatment of atopic dermatitis that incorporate new targets and mechanisms of action. Ca2+ ions are the death signal for neurons. Since the observation that no neuron regeneration takes place after surgical sectioning of the glossopharyngeal nerve, it has been pinpointed that Ca2+ ions are the main signals that initiate the death program in neurons. Our group discovered that it is the N-methyl-d-aspartate (NMDA) receptor, that enables the entry of Ca2+ ions into neurons; as we found, this receptor can be blocked by memantine, a finding that has been confirmed. In addition to their importance for cell function and survival, an overload of neurons with Ca2+ ions leads to apoptotic cell death, as reported. Here, Na-polyP acts as an opponent, compensating for the metabolic energy deficiency, particularly at those sites in the body where regeneration takes place. There are two properties of Na-polyP that crucially contribute to the unprecedented properties of this polymer (): first, the generation of metabolic energy through the transfer of the potential Gibbs free energy (ΔG) stored in its phosphoanhydride bonds to form ADP and subsequently ATP, using the enzymatic activity from the two enzymes alkaline phosphatase (ALP) and adenylate kinase (ADK); and second, the chelation of Ca2+, which leads to formation of a coacervate; the coacervate attracts stem cells, such as the interfollicular epidermal cells in the basal layer of the skin that give rise to keratinocytes (). The extracellular space is extremely poor in ATP, with 20–100 nM, compared to the very high ATP levels in the intracellular compartment of 3–10 mM. Comparable low is the concentration of ATP in mammalian erythrocytes with only 360 nM; these cells lack mitochondria. The metabolic energy of ATP is condensed in its energy-rich linkages, the phosphoanhydride bonds. As highlighted first by Lipmann, ATP is the central energy transfer molecule in cells, allowing the conversion of metabolic energy into chemically usable forms of energy. We have shown that polyP, with its up to thousand phosphate (Pi) units linked via such high-energy anhydride bonds, concentrates much more Gibbs free energy compared to ATP (total ΔG° of twice −30.5 kJ mol−1 plus one adenosine–phosphoric acid ester bond with −15 kJ mol−1), which is released upon hydrolysis of these bonds; for a polyP chain with 40 Pi units, the average length of mammalian polyP, this energy amounts to approximately −1170 kJ mol−1. The size of the polyP released from the blood platelets, the main polyP storage cells, into the circulating blood ranges between polyP60 (Pi = 60) and polyP100 (Pi = 100); such chains concentrate a ΔG° of −1800 to −3020 kJ mol−1. The ΔG° in these polymers can be released by sequential enzymatic cleavage by ALP or utilized by phosphotransfer to AMP to form ADP, which is subsequentially converted to ATP via the ADK reaction. As summarized by Schröder et al., polyP has been identified in every animal tissue examined so far, from the mouse heart (≈114 μM), brain (≈95 μM), and lung (≈91 μM) to the kidney (≈64 μM). Lower amounts of polyP are found in the liver (≈38 μM); higher levels are present in mast cells and especially in platelets (up to 1.1 mM). An increase in the intracellular Ca2+ level is a prerequisite for platelet activation by agonists such as thrombin, collagen, or ADP. The main transporters/exchangers in the platelet outer membrane are the Na+/Ca2+ exchangers (NCX). They belong to the P-type ATPase family, which directly uses the energy of ATP for their transport function. The extracellular Ca2+ level is high at 1–5 mM, while the intracellular concentration is around 10−7 M. The NCX exchangers are bi-directional transporters that stabilize Ca2+ homeostasis in the cytosol, where the Ca2+ level is ≈10−7 M. The second remarkable property of polyP, particularly characteristic for Na-polyP, is its ability to scavenge Ca2+ under formation of a coacervate. Neurons have been shown to undergo at least two Ca2+-dependent degeneration processes or apoptotic programs: an active coordinated, regulatable self-destructive apoptotic program, and a second, caspase-dependent programmed cell death. Using embryonic neurons, we were able to demonstrate that neuronal cell death is causatively induced by an intracellular Ca2+ increase. This Ca2+ burst can be neutralized by externally supplied Na-polyP via the coacervation process, thereby removing the Ca2+ ions from the cell environment, as shown in the present study. At the current stage of development, the in vivo use of Na-polyP to protect patients from disorders of the central nervous system (CNS), such as Alzheimer's dementia, is not possible. However, it is possible to apply the polymer – in an experimentum crucis – for conditions involving the peripheral nervous system (PNS), under the supervision of a physician and in accordance with §37 of the Declaration of Helsinki. In our study, we have chosen the skin condition atopic dermatitis as the clinical indication. The skin is known to be an outpost of the nervous system and the primary sensor for both harmful and innocuous external stimuli. It is densely innervated with somatosensory neurons that protrude sensory axons (afferents). The itch cycle in atopic dermatitis patients involves the release of Ca2+ from mast cells in response to immunoglobulin E (IgE) receptor-mediated signaling. Importantly, this mast cell response is preceded by coupling with the intracellular Ca2+ sensor STIM1, a transmembrane channel for Ca2+. Mast cells are the main effector cells controlling allergic reactions, as, upon activation by IgE antibodies, they secrete histamine together with a series of inflammatory and immunomodulatory substances. These cells release Ca2+ from the intracellular stores of the endoplasmic reticulum via STIM1/Orai1-mediated store-operated calcium entry receptors. This increase in intracellular Ca2+ levels leads to degranulation of the mast cells. In addition to neurons, megakaryocytes and, most likely, the platelets derived from them also express the NMDA receptor on their cell surface. This receptor allows an influx of Ca2+ into the respective cells. Subsequently, to restore ionic balance, the Ca2+ ions are transported out of the cells via the ubiquitous plasma membrane Ca2+ ATPase (PMCA). In the present contribution, we describe that Na-polyP, included in a gel/crème basis, unexpectedly alleviates atopic dermatitis lesions. The aim of this study was to demonstrate that the Ca2+ burst around the damaged tissue is eliminated after application of Na-polyP. In this treatment, the Na+ anion of the polymer is exchanged for Ca2+, thereby reducing the Ca2+ accumulation. No side effects have been reported. Materials and methods Isolation and cultivation of neuronal cells Primary neuronal cells Brain cells from 19-day-old Wistar rat embryos were dissociated with 0.025% trypsin in Hanks’ balanced salt solution (without Ca2+ and Mg2+). The cortical neuronal cells were cultivated in Hanks’ balanced salt solution and then transferred to Dulbecco's modified Eagle's medium (4500 mg L−1 glucose) (D6429, Sigma), enriched with 100 mU L−1 insulin, l-glutamine, 10% fetal calf serum, and further supplements, as described before. To enrich the neuronal cell population, proliferation of astrocytes (a subtype of glial cells) was inhibited for 3 days using 10 μM uridine, 10 μM fluoro-deoxyuridine, and 1 μM cytosine arabinofuranoside (to eliminate proliferating non-neuronal cells) for 3 days. Immunostaining with anti-68 kDa neurofilament as a marker for neurons and anti-glial fibrillary acidic protein for glial cells indicated that the cultures contained >85% neurons. To obtain a neuron glial mixed cell population, the neuronal cultures were not treated with cytostatic agents. In experiments investigating the effect of Na-polyP on the histamine-induced apoptosis, a non-toxic concentration of 1 μM or 100 μM histamine was used. To prevent this effect, a concentration of 50 μg mL−1 Na-polyP was sufficient. The protective effect was demonstrated already after 1 d. PC12 cells In one series of experiments, neuronal PC12 cells (rat pheochromocytoma cells; #88022401, Sigma), which can differentiate to neuron-like cells with neurite protrusions, were used. The cells were cultivated in RPMI 1640 medium (Sigma) containing heat-inactivated horse serum (10%)/heat-inactivated fetal bovine serum (5%) and gentamicin, as described. The medium was adjusted to 1 mM Ca2+. After an overnight pre-incubation, a solution containing 600 μg mL−1 Na-polyP or 2 μM serotonin (H9523; Sigma) in medium was added to the cultures to achieve a final concentration of 30 μg mL−1 and 100 nM, respectively, and incubation was continued for 0 to 72 h. Primary endothelial cells Cultivation of human umbilical vein endothelial cells (HUVEC; C-12200, Sigma) was caried out in endothelial growth medium (Lonza, Basel, Switzerland), enriched with 4%[v/v] fetal bovine serum (FBS; F7942, Sigma) and 0.4% bovine brain extract (BBE; CC-4098, Lonza), as previously described. HUVEC cells have the potential to differentiate via pluripotent stem cells (HiPSC) into neurons and/or astrocytes – and in addition they are synthesizing collagen type IV. This collagen is essentially needed for wound healing. The cells were seeded at a density of 5 × 103 cells per cm2 in 12-well tissue culture plates and incubated for up to 2 d. Subsequently, 600 μg mL−1 Na-polyP dissolved in medium was added to the cultures to achieve a final concentration of 30 μg mL−1 Na-polyP, and incubation was continued for 2 days. Where indicated, the cells were stained with Masson's trichrome stain. Signals were quantitatively analyzed using the Image J. Determination of intracellular Ca2+ concentration For these experiments, we followed the described procedure. Neuronal cells were loaded with the Ca2+ indicator Fura 2-AM (#47989; Sigma), dissolved in DMEM : HG serum-free medium (ADD651C; Sigma), enriched with 1% BSA (bovine serum albumin), and incubated for 30 min at 37 °C. After washing the cultures with PBS (phosphate buffered saline; P2272, Sigma), the cells were cultured for another 30 min at 37 °C. After the incubation time specified in the figures, the neurons were stimulated with 200 μM l-glutamate and 50 μM glycine in Ca2+-containing Locke's solution [154 mM NaCl, 5.6 mM KCl, 3.6 mM NaHCO3, 2.4 mM CaCl2, 5.6 mM glucose, and 10 mM HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid); pH 7.4] and the changes in the intracellular Ca2+ level were recorded. Prior to stimulation with glutamate and glycine (Glu and Gly), the neurons were exposed to histamine in the absence or presence of Na-polyP by pre-incubating the cultures with histamine at a final concentration of 1 μM or 100 μM and 50 μg mL−1 Na-polyP (average chain length ≈50 Pi units) in serum-free DMEM : HG medium. In the controls without histamine and Na-polyP, only 200 μM glutamate and 50 μM glycine were added at the start of the Ca2+ measurements. The Ca2+ level was measured using an Olympus IX70 microscope connected to an Uapo40X:340 apochromatic reflected light fluorescence objective, illuminated alternately with light at wavelengths of 340 nm and 380 nm. Recording was performed with a CCD camera, model C2400-77 (Hamamatsu, Herrsching, Germany). Subsequently, the fluorescence ratios at 340 : 380 nm were determined; the emission peak remains at 510 nm. Data are means ± SEM; 10 independent experiments were performed. Application of Na-polyP for healing of atopic dermatitis Human atopic dermatitis lesions Ethics: All experiments were performed in accordance with the Guidelines of §37 of the Declaration of Helsinki and experiments were approved by the ethics committee at University Medical Center of the University Mainz. Informed consents were obtained from human participants of this study. The first patient was a 27-year-old female with atopic dermatitis diagnosed in childhood; at the start of treatment, she was suffering from an acute flare-up. Previously, she received only topical treatment with steroids and light therapy. Prior to treatment with Na-polyP, she had received the steroidal crème Prednicarbate ((11β)-17-[(ethoxycarbonyl)-oxy]-11-hydroxy-21-(1-oxopropoxy)-pregna-1,4-diene-3,20-dione), sometimes flanked by light therapy. She intended/desired to become pregnant again and had concerns about the side effects of systemic therapy. Therefore, she wished to undergo treatment using only topical medications. After extensive clarification by the attending physician, she agreed to use the newly developed Na-polyP skin crème, containing the GMP-compliant Na-polyP. The permission for the Na-polyP-GMP has been granted and registered under the Certificate no: DE_RP 01_GMP 2023_0029. To evaluate the effectiveness of polyP, it was tested in a head-to-head comparison on both elbows. The right elbow was treated with a cortisone cream, while the new formulation containing polyP was applied to the left elbow. The initial Itch-Score (VAS) was assessed at 7/10. The DLQI (Dermatology Life Quality Index; a questionnaire designed to measure how much a skin problem has affected a person's life over the past week) was 24; and the EASI and SCORAD (an assessment tool (gold standard) designed to measure the extent and severity of eczema, a skin inflammation characterized by reddish, itchy, and swollen skin) was 25.4 and 68.5, respectively. The same ethical precautions as with the patient before were followed for the second patient, a 78-year-old lady. She complained to her dermatologist for severe itching. During the first course of treatment, the dermatologist diagnosed psoriasis and treated her in turn with Bimzelx (a monoclonal antibody for treatment of adults suffering from moderate to severe plaque psoriasis). Since, after this treatment, no objective improvement was observed, the physician specified his assessment and diagnosed atopic dermatitis. Also, the characteristic red spots did not disappear. Then she wanted to continue with cortisone. After consulting one of the authors (H.N.), she was introduced to the polyP-GMP hydrogel. Then she began using this Na-polyP containing hydrogel. After application for 3 h, she noticed pronounced and sustainable reduction of the severe itching symptoms. After six days, both the itching symptoms and the dark spots disappeared and never came back again. Another interesting aspect of this patient was the fact that atopic dermatitis also spread along the legs, preferentially at the joints of the patient. In turn, the patient has been advised by the dermatologist to apply the polyP-GMP hydrogel on the dark spot areas. As imaged, after treatment of these areas with the polyP-GMP hydrogel, the dark spots at these regions also disappeared sustainably. Preparation of Na-polyP The starting material for the Na-polyP polymer was prepared from sodium-phosphate (NaH2PO4; S5011, Sigma). The polymer was obtained by heating NaH2PO4 to 750 °C in a muffle furnace for 3–4 h and subsequent rapid cooling. For use in humans (see above), Na-polyP was prepared under Good Manufacturing Practice (GMP) conditions. Calcium polyphosphate nanoparticles (Ca-polyP-NP; storage form of the polymer) were prepared as described previously. To determine the size of the polymer, polymerization was performed with 32P-labeled polyP, which was obtained by condensing 32P-labelled NaH2PO4. This was obtained by drying a mixture of 500 μmol NaH2PO4 with 3 mCi NaH232PO4 (specific activity 1100 Ci mmol−1; DuPont NEN) for 30 min. The specific radioactivity was 13.2 × 106 dpm μmol−1 phosphate. The signal of [32P]polyP was detected by autoradiography using a KODAK autoradiography film (F5513, Sigma). Analysis and size distribution of the labeled Na-polyP product The size distribution of the 32P-labeled Na-polyP product was determined electrophoretically using 16.5% polyacrylamide slab gels (30 × 15 × 0.3 cm; ratio of bisacrylamide to acrylamide, 1 : 20) containing 7 M urea in 1× TBE (90 mM Tris, 90 mM, borate, and 2.7 mM EDTA; pH 8.3). Samples were electrophoresed for 130 min at 8–9 W until the sample dye, bromophenol blue, had migrated ≈12 cm into the respective gel. The gels were developed in 25% methanol and 5% glycerol. This method was also used for non-labeled polyP. Preparation of the short-chain polyP Since the resulting autoradiograms showed that ≈80% of the polyP product had a size >50 Pi units, the non-labeled polymer had to be purified to a product size less than 100 Pi units. For this purpose, the method described was used. The size distribution was determined by electrophoresis in urea/polyacrylamide gels as described above. The gels were stained with o-toluidine blue. The physiologically active polyP polymer is allocated to the class of short-chain polyP molecules, which are released from platelets with a chain length of around 50 Pi units. This is also the size of the polyP polymers which are most biocompatible. In a control, the short-chain polyP was digested with the ALP (intestinal; #524572 KU, Sigma), a known hydrolytic enzyme for polyP. Reverse transcription-quantitative real-time PCR analysis The technique of reverse transcription-quantitative real-time polymerase chain reaction (RT-qPCR) was used to determine the collagen gene expression levels in HUVEC cells, as described. The cells were incubated for 2 d in medium/serum in the absence or presence of Na-polyP, as indicated with the respective experiment. The cells were then collected, and the isolated RNA was subjected to RT-qPCR. The following primer pairs, matching with the respective mouse collagen types, were used. Collagen type I, alpha 1 transcripts were amplified using the human primer pairs Fwd: 50-TACATCAGCCCGAACCCCAAG-30 [nt4003 to nt4023] and Rev: 50-GGTGGACATTAGGCGCAGGAAG-30 [nt4146 to nt4125]; product size 144 bp. As the reference gene, the human glyceraldehyde 3-phosphate dehydrogenase [GAPDH] was used (Human GAPDH; NM_008084) Fwd: 50-TCACGGCAAATTCAACGGCAC-30 [nt200 to nt220] and Rev: 50-AGACTCCACGACATACTCAGCAC-30 [nt338 to nt316; size 139 bp]. Amplification was performed in an iCycler (Bio-Rad, Hercules, CA, USA) with the respective iCycler software. After determination of the Ct values, the expression of the respective transcripts was calculated. Detection of apoptosis For quantitative assessment of apoptosis, a photometric enzyme immunoassay (Cell Death Detection ELISAplus kit; Cat. No. 11 774 425 001, Roche) was used, as described previously. Measurements were performed at 405 nm against substrate solution as a blank. The background values (incubation buffer instead of sample solution) were subtracted. Balanced elimination of NMDA receptor during histamine-induced apoptosis Two marker molecules characteristic of Ca2+-dependent apoptosis in neuronal cells—the NMDA receptor and caspase-9—were selected to monitor the progressive apoptotic elimination of neuronal cells using immunohistochemistry. Antibodies against the NMDA receptor (anti-NMDA receptor-1/GRIN1 antibody, raised in goat; #SAB2500698) and the anti-caspase-9 antibody (raised in rabbit; #SAB5700785) were obtained from Sigma. Detection of the immunocomplexes was performed using a horseradish peroxidase-conjugated secondary antibody (raised in mouse; #SAB5201891, Sigma) and the chromogen 3,3′-diaminobenzidine (#D12384, Sigma). These combinations stain the immunocomplexes dark brown. Formulation of an ointment with anti-atopic dermatitis activity A suspension of polyP (200 mg Na-polyP and 20 mg Ca-polyP-NP per 10 mL) was prepared in purified water, followed by a 15 min ultrasonication step. The suspension was filtered through a 0.2 μm PES membrane (#83.1826.001; Sarstedt, Nümbrecht, Germany). In parallel, 2 g of hydroxyethyl cellulose (HEC; #4482 – NATROSOL250 HX Pharm; Caelo, Hilden, Germany) were prepared by dissolving 20 g of 1,2-propandiol (#2554, Caelo). Then, 65 g of purified water buffered with 10 g of phosphate buffer of ≈pH 6.5 was added. This sample was heated to 121 °C under overpressure (1 bar). Finally, after cooling to 23 °C, 3 mL of the polyP suspension were added to achieve a final concentration of 600 μg mL−1 Na-polyP and 60 μg mL−1 Ca-polyP-NP. The formulation was then blended in a roll mixer for 45 min. All steps were performed under sterile conditions. The final pH of the formulation was 6.5. This 2% (w/v) hydrogel containing polyP was termed “polyP-hydrogel”. Aliquots of the gels were stored in 10 mL syringes (#4617100 V; B. Braun, Melsungen, Germany) with a Luer Lock adapter and sealing cap. Urea was added at a final concentration of 5% to improve the penetration ability and stability of the hydrogel. 1,2-Propandiol (propylene glycol) was added to impart antibacterial properties to the hydrogel, particularly against skin bacteria such as Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus hominis, and Staphylococcus capitis. Staining of cells to detect development to atopic dermatitis The initial phase of development of atopic dermatitis in a skin region is characterized by activated macrophages, which can be stained with antibodies against CD80, identifying classically activated (M1) pro-inflammatory macrophages The CD80 antibody was from Sigma (Mouse Cd80; #12519). The immunocomplexes were detected with anti-antibodies that stained them in green (Invitrogen; #A-21235 anti-Mouse IgG (H + L) Cross-Adsorbed secondary antibody, labelled with Alexa Fluor 647). They were detected with an Olympus fluorescence microscope at the excitation maximum of 650/651 nm and the emission maximum of 665/672 nm. In a control, the tissue samples were incubated with 100 μM quercetin prior to dry sectioning of the samples. Quercetin is an inhibitor of metalloproteinase-9. Microscopic analyses The SEM images were taken using a Zeiss Gemini 1530 (Zeiss, Oberkochem, Germany). For lower resolution, an ESEM XL-30 microscope (Philips, Eindhoven, Netherlands) was used. The samples were freeze-dried prior to inspection. Transmission electron microscopic (TEM) was performed using a Tecnai 12 microscope (FEI Electron Optics, Eindhoven, Netherlands), as previously described. In vivo skin irritation testing on animals and human volunteers The acute effect of the polyP preparation on skin after topical application (acute skin irritation) was tested in vivo using New Zealand white rabbits. The study was conducted in an AAALAC I-approved facility after approval by the local Ethical Committee in accordance with international laws/regulations and the Animal Welfare Officer and was based on the OECD Guidelines for Testing of Chemicals. The test substance (0.5 g; applied as a powder) was administered directly to the test sites on the skin on each side of each rabbit. The application sites were covered with a 2.5 cm × 2.5 cm gauze patch, which was fixed with non-irritating adhesive tape for 5 h. After the exposure period, the residual material was removed with water. The animals were examined for signs of erythema and edema 1 h, 24 h, 48 h, and 72 h after patch removal. The potential development of allergic contact dermatitis after topical administration of the polyP preparation to human volunteers (11 male and 4 female) was evaluated by patch testing using Finn Chambers. After 48 h, the patches were removed and the skin was evaluated for signs of localized allergic reaction at intervals of 24 h, 48 h, 72 h, and 7–10 d. Molecular modeling Molecular modeling was performed according to the study by Wang et al. The serotonin receptor was obtained from the Protein Data Bank (6B79. PDB). The serotonin molecule was drawn by using Discovery Studio and arranged with this program. Results Characterization of Na-polyP Na-polyP was prepared by polycondensation of NaH2PO4 at 750 °C. The polymer was synthesized in both an unlabeled and in a 32P-labeled form. The autoradiogram of the latter form showed that this product comprises a short-chain polyP fraction with a chain length of 1 to 80 Pi units, as well as the longer-chain form (Pi > 100) (). In a recent study, we found that the physiological chain length of polyP around Pi < 100 units, as released from platelets, shows optimal biological function; Na-polyP with a chain length of ≈50 Pi units proved to be the most suitable for cells in vitro. Considering our recent findings that polyP with a chain length of around 50 Pi units is most biocompatible, the short-chain polyP fraction was analyzed (). The results with this Na-polyP fraction showed that this polyP class was stained in the gel within the polyP chain length range of around 50 Pi units. The long-chain polyP fraction with Pi > 80 units appeared closer to the application point of the sample in the gel. In a control, the polyP was digested with the polyP hydrolyzing ALP prior to its addition to the electrophoresis gel. Subsequently, only a smear was detected in the o-toluidine blue-stained gel. Morphogenetic potential of Na-polyP and serotonin Two neuronal cell types were investigated: primary neuronal cells and PC12 cells. The primary neurons were isolated from rat embryos and purified to 70% with respect to glial cells. The compounds serotonin and Na-polyP were used because we reported in a previous study that Na-polyP protects neuronal cells from programmed cell death. Serotonin forms higher assemblies with other serotonin molecules, caused by π–π interactions of the aromatic indole rings (). On the other hand, the binding of serotonin to its receptor is mediated by ionic and hydrophobic interactions (), particularly at the binding site. Furthermore, serotonin interacts with the associated G-protein. Our model studies showed that serotonin binds along a serotonin-ribbon band adjacent to the G-subunits, particularly along the β- and γ-subunits (). There, the serotonin molecules interact primarily via ionic interactions in a ribbon-like structure (). This finding suggests that the complex acts not only extracellularly on the cell surface but also within the respective cells via its G-protein-coupled receptors (5-HT1 to 5-HT7 families) or the 5-HT3 ligand-gated ion channel. This binding initiates intracellular second messenger cascades such as cAMP, IP3, or Ca2+ influx. Furthermore, published data also supports a distinct intracellular signaling route. Na-polyP: induction of neurite outgrowth Based on the finding that Na-polyP undergoes a coacervation in the presence of Ca2+, thereby allowing ATP generation, we investigated those monoamine neurotransmitters that could be modulated by a Ca2+ burst. Focusing on serotonin, it is well established that the neuroprotective effect of this transmitter correlates with the prevention/attenuation of pathological Ca2+ bursts. However, Ca2+ bursts also cause plasticity and adaptation in neurons. A loss of regulation leads to destructive processes and, if the dysregulation persists, to chronic brain injuries and often to apoptosis. Therefore, we investigated the effect of serotonin and Na-polyP in the absence or presence of Ca2+ on the viability and morphogenesis of neuronal PC12 cells. As a model, we have chosen PC12 cells, a rat pheochromocytoma cell line, because these cells do not exhibit a marked tendency to form neurites. As outlined, neurite outgrowth is guided along a 200–1000 nM Ca2+ gradient. This process is driven by cytoskeletal dynamics and, most notably, runs parallel to extracellular gradients of nerve growth factor. PC12 cells were exposed to the medium containing, in addition to Na-polyP, 1 mM of Ca2+ to allow coacervation to occur. Ca2+ was added to guide the outgrowing neurites and support Ca2+ signaling during cell movement (). Under these conditions, but even in the absence of Ca2+, after addition of Na-polyP alone, neurite outgrowth occurred (), most likely promoted by the ATP generated from the polymer. It is assumed that in the absence of additional Ca2+, Na-polyP induces morphogenetic potency by channeling endogenously stored Ca2+via the Ca2+-pumps of the sarcoplasmic/endoplasmic reticulum. These cations are released into the cytoplasm via the InsP3 receptor and intracellular calcium channels, the ryanodine receptors, in neurons and muscles, and from there out of the cells. This makes Ca2+ available in PC12 cells to guide the neuronal growth cone, the neurites at the ends of axons, along the Ca2+ gradient and to promote additional neurite formation (). Effect of serotonin on neurite outgrowth It is established that serotonin is an inducer of neurite outgrowth. The morphogenetic effect of serotonin on neurons has been confirmed; what is new is that PC12 cells also respond in this way (). It is remarkable that co-incubation with Na-polyP and Ca2+ enhances this property; this is visible after 5 and 7 days of incubation (versus), most likely due to the metabolic energy supply from Na-polyP. Prevention of histamine-caused apoptosis by Na-polyP In neuronal tissue, two monoamines (biogenic amines) with opposed functions, both derived from amino acids via decarboxylation, exist, and therefore also in the skin. Firstly, histamine, which is synthesized from histidine (via histidine decarboxylase), and secondly, serotonin (5-hydroxytryptamine, 5-HT), which is formed from tryptophan (via 5-hydroxytryptophan). They are functionally different; while serotonin has a neuroprotective effect, histamine is neurotoxic. Exposure of mixed neuronal/glial cells to 100 μM or 1 μM histamine led to a progressive apoptosis process after an exposure period of 24 h (right panel of ; ). Interestingly, but as expected from previous data, co-application of 50 μg mL−1 Na-polyP almost completely prevented this programmed cell death; the cells showed a physiological growth pattern (right panel of ; ). We explain this finding by the coacervate formation, which occurs during apoptosis by exchange of the cations Na+ and Ca2+. As direct proof that Na-polyP suppresses the Ca2+ burst around the mixed neuronal/glial cell culture, the cells were exposed to 100 μM or 1 μM histamine. The maximum fluorescence ratio decreased from 2.45 (100 μM histamine; the neurons undergo apoptosis; ) to 2.3 units (1 μM histamine; the neurons are less affected; ). A further reduction in the ratio was measured when the 100 μM histamine was co-incubated with 50 μg mL−1 Na-polyP (). This result confirms the fact that the Na+ is exchanged for Ca2+ at the polyP polymer (back to a normal neuronal growth pattern). The kinetic data further show that after reaching a maximum peak ratio (340 nm/380 nm) of >1.8, the kinetic curves decline; this finding might be partially due to photobleaching (). As shown in , the increase in the intensity of the Fura-2 fluorescence was measured almost immediately after addition of glutamic acid (Glu) and glycine (Gly). The exposure of the neurons to 1 μM histamine started 20 min prior to stimulation with Glu and Gly. When the cells were transferred to a solution with 50 μg mL−1 Na-polyP for 10 min prior to the addition of Glu and Gly, the Fura-2 fluorescence remained uniformly blue, indicating the absence of any significant intracellular Ca2+ accumulation (). On the top, a ratio scale of the Fura-2 fluorescence is shown. Quantification of the effect of Na-polyP on apoptosis of neuronal cells The effect of Na-polyP on the degree of apoptosis in neurons induced by histamine was measured using a photometric enzyme immunoassay (cell death detection ELISA), which enables the measurement of apoptosis by quantifying cytoplasmic histone-associated DNA fragments. As shown in , exposure of the neurons for 72 h with 100 μM histamine markedly increased the extent of apoptosis of the cells; at a concentration of 1 μM, histamine was less active. Addition of Na-polyP after an incubation period of 24 h significantly reduced the degree of apoptosis (A405 nm value) by ≈50% compared to the cultures without Na-polyP addition. Elimination of the NMDA receptor and of the final apoptotic caspase-9 after exposure to 100 μM histamine Based on our immunohistological data, we found that during the exposure to histamine both caspase-9 and the targeted NMDA receptor are engulfed in apoptotic bodies (). This finding was surprising, as this process implies that histamine self-organizes the apoptotic elimination of the key apoptosis-controlling molecules, the NMDA receptor () and the executioner caspase, the caspase-9 (). Addition of 50 μg mL−1 Na-polyP inhibits this process. In the presence of this chelating polymer, only less than 5% of the neurons undergo the “physiological” apoptotic process and form apoptotic bodies (). Increased collagen fibrillogenesis after exposure to Na-polyP In atopic dermatitis, the collagen network in the epidermis and dermis is severely impaired due to an impaired synthesis of collagen types I, III, and IV, compared to healthy skin. The consequences are defects in the skin barrier function. Fibroblasts and keratinocytes are the cells affected. In addition to enzymatic dysfunctions, a deficiency in the key enzymes of collagen processing, the metalloproteinases, can lead to an atopic dermatitis phenotype. This deficiency can be compensated for by supplementing the growth medium for endothelial HUVEC cells (human umbilical vein endothelial cells) with the metabolic energy-generating Na-polyP. In the present study, we used HUVEC cells to analyze the collagen expression-enhancing effect caused by Na-polyP. In the HUVEC system, collagen synthesis was found to increase continuously during the 2 d incubation period, as shown by staining with Masson's trichrome (). The intensity of Masson's trichrome stain was quantitatively assessed using ImageJ (). Submicroscopic visualization was performed using ESEM microscopy. The images show that in the absence of Na-polyP (), no fibrillar structures are visible around the HUVEC cells even after a 48 h incubation period. These cells are known to produce both type IV collagen, which is essential for the formation of the basement membrane, and type I collagen, which is involved in the formation of the large fibrils in connective tissue. However, in the presence of 30 μg mL−1 of Na-polyP (), the initially spindle-shaped HUVEC cells begin to form fibrils (), which assemble into collagen bundles (). At higher magnification, the fibrillar arrangement of the bundle precursors is visible (). In , it is obvious that collagen fibrils are embedded in a cell-rich environment. Confirmation of the anabolic effect of Na-polyP by RT-qPCR Immediately after seeding the cells, the gene expression ratio (Col-I : GAPDH) is very low with approximately 0.3 ± 0.2 in the absence or presence of 30 μg mL−1 of Na-polyP (). Increasing the exposure period to 24 or 48 h, resp. leads to a significant increase of the expression ratio by up to 6-fold (without Na-polyP) and 15-fold (presence of Na-polyP). The differences in the expression levels between the Na-polyP-exposed to non-exposed cells are significant. In the presence of Na-polyP, the gene expression ratio was 64% (after 24 h) and even 160% (after 48 h) higher than in the absence of the polymer. Development of atopic dermatitis characterized by staining with the macrophage (M1) marker CD80 Metalloproteinases have serious effects on wounds in atopic dermatitis. In this study, CD80 was used as a marker protein to identify pro-inflammatory macrophages (M1); . After immunostaining, the sectioned samples were either used directly for histological inspection or (as a control) incubated with 100 μM quercetin, an inhibitor of metalloproteinases. shows a section through the epidermis with its stratum basale, above the papillary dermis, the stratum granulosum, and finally the stratum corneum. show schematic representations of healthy skin () and a skin region affected by atopic dermatitis () showing the main stages in the development of an atopic dermatitis phenotype, highlighting the inflammation, skin scales (dandruff) formation, and finally the itching phase. These three phases are driven by the activity of metalloproteinases, which enable the fissure phase, during which the formed cavities allow the infiltration of bacteria (), leading to inflammation. This results in activation of macrophages, especially around the hair shafts (), leading to their accumulation around the root sheaths. Finally, disintegration of the cells in the epidermal region occurs (). As a control, the biopsy specimen was incubated for 3 d with 100 μM quercetin, a period allowing to suppress the expression of metalloproteinases in the macrophages. Using the anti-CD80 antibody, it was found that in the slices the expression of CD80 was strongly reduced (). Acute dermal irritation The evaluation of the acute effect of the polyP preparation on skin was performed using two rabbits as described in Materials and methods. The administered dose was 0.5 g test substance per test site. The results are summarized in Table S1 (see SI). No clinical signs of erythema and edema after 1, 24, 48, and 72 h and no eschar formation were observed. All gratings were 0/0. Furthermore, no differences in the body weight of the animals on day 1 and day 4 was found. From these results, it was concluded that the polyP preparation is not a primary skin irritant. Patch testing in humans In the frame of a phase 1 study, the potential of the polyP preparation for development of allergic contact dermatitis was evaluated by patch testing using Finn Chambers. Fifteen volunteers of different age and gender were included in this study. The patches were left on for 48 hours, and the skin was evaluated at 24, 48, and 72 h and after 7–10 d after removal for signs of localized allergic reaction. As summarized in Table S2 (see SI), only 3 volunteers showed a slight but transient erythema at 48 h. Otherwise, no allergic reactions were observed. Application of the polymer suitable to ameliorate atopic dermatitis in an open case study Two patients were enrolled in this open case study ( and ). In both patients, very fast healing of the lesions was observed. A striking reduction of the itch score from over 7/10 to less than 2/10 were determined. The first patient, a 27-year-old woman with atopic dermatitis since childhood, experienced an acute flare-up. Previous topical treatments with steroids and phototherapy had been unsuccessful. To assess the efficacy of the Na-polyP hydrogel, a direct comparison was performed (). The right elbow of the patient was treated with a cortisone cream (), and her left elbow with the Na-polyP formulation (). The findings on admission on August 5 were: DLQI 24 and Itch score (VAS) 7/10. After one week of topical treatment (August 12), the findings were: right elbow (cortisone): itch score 4/10 (); left elbow (Na-polyP): itch score 2/10 (); and after two weeks of topical treatment (August 19): right elbow (cortisone): DLQI 7, itch score 3/10 (); left elbow (Na-polyP): DLQI 7, itch score 2/10 (). After this, the acute treatment could be completed and outpatient treatment continued. The treatment of the second patient, a 78-year-old woman (), was equally successful. After three hours of application of the polyP-GMP hydrogel, a significant reduction in itching was observed. After one to six days of treatment, the itching and the dark spots on the skin of the arm (, compared to ) and leg ( compared to ) had permanently disappeared. In parallel the CORAD index reduced from >68 to less than 20, indicating an objective and significant reduction of the atopic dermatitis symptoms. The topical polyP formulation administered to the patients had been supplemented with urea and propylene glycol, which are widely used as excipients in hydrogels to enhance the penetration ability and improve stability of the active ingredient. Urea does not possess a direct anti-inflammatory activity but acts as a soothing agent reducing skin irritation. Propylene glycol exhibits only weak local anti-inflammatory properties but contributes to the antibacterial activity of the hydrogel, which has also been shown for Na-polyP alone. Both excipients play a primarily supportive role and cannot account for the pronounced anti-atopic dermatitis activity of the polyP formulation. Stability of polyP It is well established, and we have previously confirmed, that polyP (both Na-polyP and Ca-polyP-NP) are exceptionally stable and can be stored in a dry state at room temperature for years. In addition to the undissolved polymer, solutions of the Na-polyP salt and suspensions of Ca-polyP-NP also exhibit high stability, provided they are stored at a slightly alkaline or neutral pH. However, an alkaline pH can cause skin irritation. Therefore, it was important to investigate how long the polymer remains stable when the pH of the surrounding environment is lowered. The integrity (chain length) of the polyP was analyzed via urea-polyacrylamide gel electrophoresis (as described above) after storage for various periods (1, 3, and 6 months). Our results showed that the polymer (Na-polyP and Ca-polyP-NP) remains stable over a period of 6 months when embedded in the hydrogel formulation at pH 6.5 and stored in a refrigerator at 7 °C. The degradation of the original polymer was less than 5%. Discussion Atopic dermatitis is an inflammatory, chronically relapsing, and intensely pruritic skin disease that often occurs in families suffering from the same disease or from bronchial asthma, and/or allergic rhino-conjunctivitis. Its severity is graded along the scale introduced by Hanifin and Rajka. In advanced stages of the disease, noncontagious inflammation develops in the affected epidermis and dermis region, characterized by itching, erythema, and a variety of related papules, ranging from small to extensive lichenification-related skin lesions, and a dysfunction of the keratinization process. This can lead to a compromised skin barrier function. A causal-analytical treatment or cure of atopic dermatitis is not yet available. The treatment is currently limited to symptom management. In a rational approach, we sought to understand how nature would address this problem. Our strategy is based on the following premises and requirements. Firstly, all lesions of atopic dermatitis led to bleeding or, in the final stage, to blood crusts. Secondly, every wound healing process requires metabolic energy. Thirdly, the treatment should be adaptable to individual patients. Fourthly, the treatment should have antibiotic properties. Tissue injury is usually accompanied by hemostasis and thrombosis. This author highlighted that blood platelets are not only key factors in maintaining hemostasis and controlling thrombosis but are also decisively involved in healing due to their ability to release, upon stimulation, chemokines and monoamines such as serotonin and histamine, which are derived from the corresponding amino acids. In addition, in skin inflammations such as in atopic dermatitis and systemic sclerosis, platelet hyperaggregability occurs, based on IgE-mediated sensitization to foods. Platelets also harbor nucleoside polyP derivatives such as dinucleotide polyphosphates. It is well known that platelets play a central role in atopic dermatitis. These cell fragments are filled with batteries of mediators, including the activation-regulated chemokine TARC/CCL17, serotonin, and arachidonic acid metabolites. Within this series of mediators, nature always produces both catabolically acting signaling molecules (such as histamine) and anabolically acting molecules (such as serotonin). Histamine is a neurotoxic agent, while serotonin is a morphogenetically active molecule (as reported in this study). The platelets are also filled with the anti-atopic dermatitis polymer, with Na-polyP, and the main driver of this chronic inflammatory skin condition, with Ca2+ ions. Na-polyP can chelate Ca2+ and thereby form a Ca-polyP coacervate phase; as a result, Ca2+ ions are removed from the cell environment. Although it is known that Ca2+ can help relieve atopic dermatitis when administered together with calcitriol and/or paricalcitol, there is need for an agent that eliminates the “death signal” Ca2+. In the human body, platelets contain the highest amount of polyP, which is released with a chain length of 50 Pi units and exists either as soluble, free Na-polyP or as Ca-polyP-NP. Due to the fact that this polymer has high-energy phosphoanhydride bonds, linking their Pi units, energy can be transferred by enzymatic cleavage of these bonds by ALP (phosphotransfer to AMP to form ADP) and subsequent interconversion of ADP (two molecules) to AMP and ATP. Therefore, although platelets constitute only ≈1% (450 000 μL−1) of the cellular components in the circulating blood and are present in a low concentration compared to erythrocytes (40–45%), they are considered as key regulators during any tissue injuries. In this study, we describe how Na-polyP, embedded in a gel/crème base, unanticipatedly ameliorates atopic dermatitis lesions. We were able to demonstrate that the Ca2+ burst occurring in tissue damage is eliminated following the application of Na-polyP—a treatment in which the Na+ cations of the polyP are exchanged for Ca2+, resulting in a reduction of Ca2+ accumulation. As shown, extracellular Na-polyP binds strongly to Ca2+. The affinity of polyP for Ca2+ is high, even more than for Mg2+. In addition to the Ca2+-chelating activity of Na-polyP, two further components have been included in the ointment; urea (5%) and 1,2-propandiol (propylene glycol) as an antibacterial ingredient, as mentioned above. For topical application, urea is particularly useful and indicated in the concentration range of 10–30%. In our studies, a concentration of 5% proved optimal. Urea accelerates the penetration of Na-polyP. As we previously reported, a polyP chain length of approximately 50 Pi units is required for optimal biological activity. However, these results do not imply that longer polyP chains also have similar effects due to the enzymatic degradation of the polymer by cellular enzymes, especially the ALP, which functions as the most important exopolyphosphatase in humans and is present both intracellularly and extracellularly, anchored to the cell surface via a glycosylphosphatidylinositol (GPI) anchor. The reason for this is that the enzyme degrades polyP via a processive mechanism (i.e., a polymer chain is completely degraded to monomeric orthophosphate without dissociation of the enzyme–substrate complex after each hydrolytic step). Consequently, the formation of shorter polyP chains as intermediates is not to be expected following contact between Na-polyP and cells or body fluids. Nevertheless, non-enzymatic hydrolysis of the polymer, for instance, during storage of the polyP formulation, could result in the formation of shorter polyP chains. It is known that polyP is highly stable in slightly alkaline and neutral solutions but undergoes degradation under acidic pH conditions. Therefore, we investigated the stability of the polyP formulation containing Na-polyP and Ca-polyP-NP in a 10 : 1 ratio (final concentrations: 600 μg mL−1 Na-polyP and 60 μg mL−1 Ca-polyP-NP) embedded in a hydrogel base composed of 2% (w/v) hydroxyethylcellulose (HEC), supplemented with urea and propylene glycol and adjusted to a pH of 6.5. Our studies demonstrated that the Na-polyP and Ca-polyP-NP embedded in this hydrogel base remained stable for a period of at least six months when stored in a refrigerator at 7 °C. Analysis of chain lengths using urea-polyacrylamide gels followed by toluidine blue staining revealed no significant degradation (less than 5% degradation) of the polymer. Based on the finding that Na-polyP undergoes coacervation in the presence of Ca2+, we investigated the monoamine neurotransmitters histamine and serotonin, whose effects could be modulated by the scavenging and coacervate-forming effect of Na-polyP on the established Ca2+ burst. An interesting finding was that, during the incubation of neurons with Na-polyP, the key target molecules associated with apoptosis—the NMDA receptor and caspase-9—are removed from the neurons by being sequestered into apoptotic bodies. Until now, it has not been investigated whether neuronal cells undergo morphogenesis in response to Na-polyP exposure. We have chosen PC12 cells, a rat pheochromocytoma cell line, as a model because these cells do not exhibit a marked tendency to form and initiate neurites. As previously described, neurite outgrowth is guided along a 200–1000 nM Ca2+ gradient. This process is driven by cytoskeletal dynamics and runs parallel to extracellular gradients of the nerve growth factor. In this study, we show that this polymer, Na-polyP, can induce neurite outgrowth in PC12 cells. It was striking that neurite outgrowth in PC12 cells, after exposure to Na-polyP, occurred both in the absence and presence of added Ca2+ ions (see ). It is known that the formation of neurite processes is induced by serotonin. Our results showed that co-incubation of PC12 cells with Na-polyP and Ca2+ enhances this property of serotonin. This effect could be, at least partially, due to the supply of metabolic energy from the energy-rich Na-polyP polymer. Unlike serotonin, histamine, the second biogenic amine, is the classical inducer of atopic dermatitis, even though its role is complex. Experiments have shown that histamine levels are elevated during itch sensation. Histamine induces the release of intracellular Ca2+. The Ca2+ originates from the intracellular stores of mast cells. These cells are centrally involved in the Ca2+-responsive release of histamine and Ca2+. They are released via the mast cell granules, which are filled with Ca2+. In contrast to serotonin, histamine induces apoptosis—it is neurotoxic. Activated mast cells undergo apoptosis because they are decorated with NMDA receptors. From previous studies, it is known that Ca2+ bursts can induce apoptosis. The results summarized in the present study are surprising, as our data showed that, in the presence of 50 μg mL−1 Na-polyP, the neurotoxic effect of histamine was completely abolished (see ). It has been shown that no release of histamine occurred at a Ca2+ concentration below 50 μM, but this response was restored after exposure to, at least, 1 mM Ca2+. Thus, Ca2+ acts as a switch for the release of histamine by inducing the movement of the histamine granules to the cell membrane. Focusing on the skin, in the basal layer, the stratum basale (where cells proliferate), the Ca2+ level is ≈0.4 mM, while in the stratum granulosum of the upper layer of the skin, the extracellular Ca2+ concentration reaches its peak with ≈1.0–1.5 mM, resulting in a Ca2+ gradient in the dermis and epidermis. In the outermost layer, the stratum corneum, the Ca2+ concentration drops again; there, the cation is mainly bound to extracellular proteins and lipids. The high Ca2+ level triggers differentiation processes and, by this, forms the skin barrier. The question arose as to which cells in the skin are responsible for the increase in Ca2+. It is known that, in the body, particularly in the bloodstream, platelets are the primary source of Ca2+ released into the extracellular space. Nevertheless, the intracellular Ca2+ level in platelets is very low at 10−7 M (0.1 μM), while it is high extracellularly at 1–5 mM. This large difference highlights the signaling effect of Ca2+ and the efficiency of the Ca2+ reflux systems in the platelet membrane. To achieve homoeostasis of 0.1 μM Ca2+, excess Ca2+ must be removed from the cytoplasm. Conversely, a panel of channels and pumps must balance the excess Ca2+ by removal of Ca2+ from the cytosol. The high extracellular level of Ca2+ is sufficient to induce coacervation. Importantly, megakaryocytes, and most likely also the platelets derived from them, express NMDA receptors on their cell surface. This receptor also enables Ca2+ influx into the respective cells. Apoptosis is induced by histamine following exposure to the IgE-binding FcεRI receptor. The question therefore arises as to why Na-polyP at a concentration of 50 μg mL−1, as used in this study, can counteract the deleterious effects caused by histamine alone? The most obvious explanation would be that polyP initiates coacervation and thereby eliminates or reduces the Ca2+ burst. To prove this assumption that Na-polyP scavenges extracellular Ca2+ due to an Na+/Ca2+ exchange, neurons were first incubated with 100 μM or 1 μM histamine and the glutamate-induced changes in intracellular Ca2+ level were measured using the Ca2+ indicator Fura 2-AM. It was found that the rise in intracellular Ca2+ level was abolished after addition of Na-polyP (see and ). The reduction in intracellular Ca2+ level has been attributed to an exchange of the polyP counterions (Ca2+ for Na+), resulting in the formation of a Ca-polyP coacervate phase. Certainly, a major component of the skin is collagen, which is produced in fibroblasts. In the present study, we demonstrate that collagen is actively formed in these cells after exposure to 30 μg mL−1 Na-polyP (see and ). This effect was expected, as our group has shown that polyP induces the activity of the anabolic metalloproteinases, and among this enzyme family, the metalloproteinase 9 and 2 (MMP-9 and MMP-2), which, as we have described, are strongly upregulated in HUVEC cells after exposure to polyP. In nature, there are always enzymes that not only induce a specific metabolic pathway but also act catabolically. Catabolic metalloproteinase are collagen-degrading enzymes. Interestingly, the activity and the distribution of these enzymes depend on Ca2+; even more, the balance between metalloenzymes and their inhibitors, the tissue inhibitor (TIMP-l), is disturbed in poorly healing wounds. Metalloproteinases play a key role in the development and progression of atopic dermatitis, particularly MMP-9 and MMP-8. These enzymes are activated and elevated in affected skin and contribute directly to inflammation and disruption of the skin barrier. Even worse, these enzymes migrate from the stratum basale to the stratum corneum together with the pro-inflammatory macrophages (M1) (see ). This figure shows a schematic representation of the progression of atopic dermatitis from its onset to the full-blown stage. In the present study, we used the characteristic cell marker for pro-inflammatory macrophages (M1 macrophages), the CD80 antigenic marker, since the progression of the disease is associated with increased inflammation. The images of the stage-dependent progression phases showed an increasing disintegration of cell contacts, allowing bacteria to enter the tissue fissures and disrupt the cell–cell contacts in the tissue layers (). This implies that, in atopic dermatitis, inflammation-caused wounds should be addressed. Na-polyP has proven particularly effective in promoting regeneration and successful healing, even in chronic wounds, which certainly contributes to the success of healing in atopic dermatitis. A schematic representation of the development of atopic dermatitis and the presumed mode of action of the new polyP formulation is shown in . Mast cells, acting together with Merkel cells serving as mechanoreceptors during the itch cycle, are activated after exposure to reactive oxygen species (ROS) and release Ca2+, in addition to serotonin and histamine (). Histamine is neurotoxic (induction of apoptosis), while serotonin exhibits morphogenetic activity (induction of neurite outgrowth). Ca2+ ions play a predominant role in the progression of the disease. The Ca2+ supply inside and outside of the cells is controlled by a multifold of channels (). The largest intracellular Ca2+ reservoir is the endoplasmic reticulum, where this cation accumulates to a concentration of up to 10−3 M. In response to ROS, the mast cells also release histamine. The mast cell granules containing histamine, as so-called “secretory lysosomes”, trigger the allergic and even anaphylactic symptoms through the release of histamine. In 1985, Erne and Pletscher, already showed that histamine activates platelets via induction of thrombin, ADP, and collagen and cause a rise in intracellular Ca2+. Exactly these cell fragments, the platelets subsequently compensate for the resulting imbalance between intracellular and extracellular Ca2+ level. To enable this, platelets are provided with channels embedded in the cell membranes, which either enable the transport of Ca2+ into the cytosol or out of the cell through the plasma membrane;. There are all splice variants from the NCX3 transcripts. The NCX 3.2 receptor allows the influx of Ca2+ into the respective cells. To subsequently restore the ionic balance, the Ca2+ ions are transported out of the cells by the ubiquitous plasma membrane Ca2+ ATPase (PMCA), which acts as a Ca2+ pump removing Ca2+ from the cytosol. This enzyme is ATP-dependent and activated by longer-chain polyP. It should be noted that the Ca2+ level in the endoplasmic reticulum is similarly high at ≈3 mM as in the extracellular space. In atopic dermatitis, even small changes in the extracellular Ca2+ levels cause an activation of mast cells. The result is an increased release of histamine. It should be emphasized that the anti-atopic dermatitis agent identified in this study, polyP, has been recognized as safe for use as a food additive by the US Food and Drug Administration (FDA) and the European Union (EU), and in humans as well. Recently, in a first-in-human clinical trial, the safety, feasibility, and osteo-inductivity of Ca-polyP-NP have been evaluated. In this single-blinded, parallel, prospective pilot study, Ca-polyP-NP has been applied either alone (1 g in 1.5 mL saline) or in combination with biphasic calcium phosphate (BCP; composed of 60% hydroxyapatite and 40% β-TCP) (1 g Ca-polyP-NP and 2 g BCP in 3–5 mL saline) for alveolar cleft repair. Based on the results, it was concluded that Ca-polyP-NP is a safe material. None of the patients developed allergic reactions or showed other local or systemic adverse effects. PolyP is listed under the E-numbers E 452 (Na-polyP), E 452 (Na/Ca-polyP), and E 452 (Ca-polyP). The LD50 for Na-polyP is >10 000 mg kg−1 (rats). Furthermore, Na-polyP shows no carcinogenicity. Therefore, there are currently no obstacles that could prevent the further development of Na-polyP into a clinically applicable drug for the prevention of atopic dermatitis. Conclusions The data summarized in the present study demonstrate that Na-polyP is an effective ameliorating polymer for reducing or even healing atopic dermatitis lesions. The basis is the chelating potential of Na-polyP. It might be highlighted again that a further outcome of this study is that Ca2+ ions are extruded from the cells primarily via the ATP-dependent PMCA channel and the NCX3.4 Na+/Ca2+ exchanger present in the platelet plasma membrane (). With Na-polyP, a new polymer is introduced that is even superior than cortisone, until now the most frequently used ointment to treat atopic dermatitis.